Growing revenue Viva Biotech reports robust revenue up to RMB 1,006.5 million with a 34% gross margin as of Jun 30, 2026, indicating a healthy financial position to scale partnerships and pursue larger collaboration contracts or multi-year CRO/CMC service agreements.

Integrated services One-stop offerings spanning early-stage structure-based drug discovery to commercial manufacturing, plus CMC via Langhua Pharma, present opportunities to upsell end-to-end programs to biopharma and biotech partners seeking streamlined vendor management.

AI and automation Active AI-driven initiatives and collaborations with NVIDIA, EnsembleCycPerm for cyclic peptide permeability, and AI partnerships suggest opportunities to sell advanced computational biology, data analytics, and model-informed discovery services to accelerate programs.

Global collaborations Recent partnerships with Adjutor Healthcare and Qubigen, plus a track record of international collaborations, position Viva Biotech to expand geographic reach and co-development deals with mid-market and emerging pharma companies seeking global access.

Industry recognition Frost & Sullivan 2025 APAC Technology Innovation Leadership award reinforces credibility for pitching advanced discovery platforms, higher-tier service agreements, and longer-term strategic partnerships as a differentiator against competitors.